Brussels, 29 May 2013
12.00 – 14.00
At world level, the issue of access to medicines encompasses all aspects of what is involved in making sure that drugs and treatments are delivered appropriately. WHO Member States are now working to ensure and sustain equitable universal health coverage and a transition is under way towards greater reliance on domestic healthcare financing to guarantee viable access to medicines.
While Europe witnesses significant reform of its various healthcare systems, the European model is used as a reference point elsewhere in the world. Emerging countries like India are both learning from European systems and devising their own quite different solutions. The question of how to balance equity and efficiency is common to all, while national contexts remain fundamentally diverse.
For the pharmaceutical sector, the subject of access to medicines in developing countries raises challenging questions. Research prioritization, supply chain, pricing solutions and the adequacy of healthcare funding are only some questions in this debate. Companies are adapting their business practices and models to access new markets while at the same time making their medicines accessible in a sustainable and effective way.
I look forward to seeing you at the debate on 29 May.
12h00 Buffet Lunch
12h20– 12h25 Welcome by Gay Mitchell MEP
12h25 – 13h25 Stakeholders’ Perspectives
· Dr Richard Laing, WHO Medical Officer on the Priority Medicines for Europe and the World
· Dr Manika Balasegaram, Executive Director, Médecins Sans Frontières Access Program
· Konji Sebati, Director of the Department for Traditional knowledge and Global Challenges at WIPO
· Dr Guy Nuyts, Director of the Regional Pricing and Access EMEA at Janssen Pharmaceutical Group, Johnson & Johnson
13h25 – 13h50 Questions & Answers with guests
13h50 – 14h00 Conclusion by Gay Mitchell MEP
Please confirm your participation by latest 20 May 2013 to Raquel Resendes, Assistant Manager, Government Affairs, EFPIA – email@example.com